Results 181 to 190 of about 104,823 (289)

Intravitreal bevacizumab for macular edema due to branch retinal vein occlusion: 12-month results

open access: yes, 2011
Mehmet Demir, Ersin Oba, Gökhan Gulkilik, Mahmut Odabasi, Erhan OzdalSisli Etfal Training and Research Hospital, Eye Clinic, Sisli, Istanbul, TurkeyPurpose: To present the functional and anatomic changes after intravitreal bevacizumab in eyes ...
Demir M   +4 more
core  

A guide to the types, structures, and multifaceted functions of matrix metalloproteinases in cancer

open access: yesThe FEBS Journal, EarlyView.
Matrix metalloproteinases (MMPs) orchestrate cancer progression and metastasis through proteolytic and non‐proteolytic actions. By remodeling the tumor microenvironment, enhancing growth factor availability, and modulating cell behavior, MMPs promote proliferation, migration or invasion, and epithelial‐to‐mesenchymal transition. Alongside extracellular
Zoi Piperigkou   +4 more
wiley   +1 more source

Behind the scenes: how the EMILIN/Multimerin family shapes the cancer landscape

open access: yesThe FEBS Journal, EarlyView.
The EMILIN/Multimerin family members regulate key hallmarks of cancer—including apoptosis, angiogenesis, metastasis, and tumor microenvironment remodeling. As indicated, their function in immune evasion, drug resistance, and metabolic reprogramming remains largely unexplored.
Evelina Poletto   +9 more
wiley   +1 more source

Bevacizumab for Radiation-Induced (Radiculo)plexopathy. [PDF]

open access: yesEur J Neurol
Picca A   +7 more
europepmc   +1 more source

Changing from bevacizumab to ranibizumab in age-related macular degeneration. Is it safe?

open access: yes, 2009
Dimitrios A Karagiannis1, Ioannis D Ladas2, Efstratios Parikakis1, Ilias Georgalas2, Athanasios Kotsolis2, Giorgos Amariotakis1, Vasileios Soumplis1, Panagiotis Mitropoulos11Ophthalmiatrio Eye Hospital of Athens, Athens, Greece; 2First Department of ...
Efstratios Parikakis   +3 more
core  

Clinical Significance of Anti‐Atezolizumab Antibodies in Patients With Unresectable Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab

open access: yesHepatology Research, EarlyView.
ABSTRACT Aim Systemic therapy is required for unresectable hepatocellular carcinoma (HCC). Atezolizumab plus bevacizumab (ATZ/BEV) is the recommended first‐line treatment for HCC; however, the development of anti‐drug antibodies (ADAs) against ATZ may impair its therapeutic efficacy. Although ADAs have been reported in other cancers treated with immune
Keishi Ouchi   +8 more
wiley   +1 more source

Comparison of outcomes of second-line durvalumab plus tremelimumab versus lenvatinib following first-line atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. [PDF]

open access: yesPLoS One
Nishioka C   +25 more
europepmc   +1 more source

Preventive Effect of Mineralocorticoid Receptor Antagonists Against Proteinuria Induced by Atezolizumab Plus Bevacizumab Therapy in Hepatocellular Carcinoma: A Multicenter Retrospective Study

open access: yesHepatology Research, EarlyView.
Mineralocorticoid receptor antagonists are known to reduce proteinuria in chronic kidney disease, but their effectiveness in preventing bevacizumab‐related proteinuria has not been well established. In the present multi‐institutional retrospective study, we found that these agents significantly delay the onset of moderate or higher grade proteinuria ...
Tomoki Hori   +17 more
wiley   +1 more source

Updates and controversies in contemporary grading of clear cell renal cell carcinoma and papillary renal cell carcinoma

open access: yesHistopathology, EarlyView.
New concepts, innovations and some issues have emerged since the adoption a decade ago of WHO/ISUP grading for CCRCC and PRCC. Continued use of the WHO/ISUP grading for CCRCC and PRCC has been upheld by newer studies, and practice guidance for some of the grading issues, where data are available, is provided.
Gladell P. Paner   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy